Prescription Required.Why?
A sodium-glucose co-transporter 2 (sglt2) inhibitor.
A dipeptidyl peptidase-4 (dpp-4) inhibitor.
Treatment of type 2 diabetes mellitus in adults, particularly those who have not achieved adequate glycemic control with metformin alone or other suitable oral agents.
Dapagliflozin works by blocking SGLT2 in the kidneys, increasing glucose excretion in the urine. Linagliptin inhibits DPP-4, leading to increased levels of incretins, which stimulate insulin release and suppress glucagon secretion. This combination offers a dual mechanism for improved glycemic control.
Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.
Dosage should be determined by a healthcare professional based on individual patient needs and response.
The typical starting dose is one tablet daily.
Dosage should not be changed without consulting a healthcare provider.
Urinary tract infections (UTIs).
Genital mycotic infections (yeast infections).
Increased urination.
Dehydration.
Hyperkalemia (high potassium levels).
Nausea, vomiting, diarrhea.
Headache.
Alcohol may increase the risk of hypoglycemia. Moderate alcohol consumption should be discussed with your doctor.
Hypoglycemia can impair alertness and concentration. Avoid driving or operating machinery if experiencing hypoglycemic symptoms.
Consult your healthcare professional before using this medication during pregnancy or breastfeeding. Use is generally not recommended during pregnancy.
Not recommended for use in children.
Caution is advised in patients with moderate to severe kidney impairment. Dosage adjustment may be necessary.
No significant dosage adjustment is usually needed in patients with liver impairment, but monitoring is recommended.
Consult your physician or pharmacist for specific prescribing information and references to the drug's package insert and clinical trials.
